Iavarone M, Invernizzi F, Czauderna C, et al. - Researchers conducted a retrospective, multicentre, international study of 28 regorafenib-treated liver transplantation (LT) patients (57 years, 7% cirrhotics, 54% performance-status 1) (2015-2018), in order to assess the safety and efficacy of regorafenib as second-line treatment for hepatocellular carcinoma (HCC)-recurrence after LT. At least 1 adverse event (AE) was reported in all patients during regorafenib (6.3 months), the most common grade 3/4 AEs were fatigue (n = 7) and dermatological reaction (n = 5). While there was no liver rejection and there appeared an increase in plasma levels of immunosuppressive-drugs in 5. For the first time, this study demonstrated regorafenib as safe after LT. Hence, the rationale of considering regorafenib in sorafenib-tolerant patients with HCC-recurrence after LT in the clinical decision-making was supported.